HeartSine® was founded in 1998 to continue innovative development of advanced lifesaving products for the treatment of Sudden Cardiac Arrest. Our passion to innovate began in 1967, when we invented the first mobile defibrillator and changed the way the world delivered emergency care. In the years since, HeartSine has continued its passion to innovate by advancing mobile defibrillation and lifesaving technology.
By providing technologically advanced, easy-to-use, affordable AEDs for home and public access markets, HeartSine continues to provide medical devices that save lives.
Our flagship product, the samaritan® PAD (Public Access Defibrillator) which is designed for use by rescuers of all skill levels, has been deployed in thousands of facilities. HeartSine AED products are currently available in 29 languages and are saving lives in more than 40 countries.
Being the technology leader in the global AED industry enables us to offer the best of all worlds in the clinical performance, durability and cost of ownership of AEDs. As a result of our leadership position, HeartSine samaritan PAD is recognized around the world for lifesaving technology.
We are committed to providing innovative, intelligent, lifesaving solutions for the assessment and prevention of sudden cardiac death. Our mission is to:
- Expand the frontiers of medical research with patented technologies that address clinical requirements and meet the needs of the market with unsurpassed quality and reliability
- Deal with customers and suppliers with the highest level of ethics and fairness
- Employ high-quality and motivated employees and promote an optimal environment for them through respect, a good workplace and rewards
- Offer products at a fair price, strive to reduce costs and earn a reasonable profit
Research and Development
HeartSine’s technology and innovation is based on a proven history of development in the field of cardiac defibrillation that began in the 1960s. Our R&D is spearheaded by an impressive team of technology experts and renowned luminaries in the industry.
A renowned panel of key authorities in the field of resuscitation employ their wealth of clinical experience on our Clinical Advisory Board to support our development of ground breaking innovative technology. The board’s prominent members include Dr. Ben Abella, Dr. Rudi Koster, Dr. David McEneaney, Dr. Doug Weaver and Chair Prof. Jennifer Adgey.
To augment and enhance our in-house development activities, we have established links in Northern Ireland with the University of Ulster, Northern Ireland Ambulance Service, Craigavon Area Hospital and the Royal Victoria Hospital, a world renowned teaching and research hospital on our doorstep. In addition, we have initiated research with University of Pennsylvania and Penn Presbyterian Medical Center, the world leading institution for the advancement of resuscitation therapies.f